1. European Medicines Agency (EMA), Temporary interim limits for NMBA, DIPNA, EIPNA, impurities in sartan blood pressure medicines. EMA/351053/2019 rev 1., 2019.
2. Structure-based thresholds of toxicological concern (TTC): Guidance for application to substances present at low levels in the diet;Kroes;Food Chem. Toxicol.,2004
3. SwissMedic, Potential nitrosamine contamination, (n.d.). https://www.swissmedic.ch/swissmedic/en/home/news/mitteilungen/aufforderung-zlinhaberinnen-ham.html, (accessed June 22, 2021).
4. European Medicines Agency (EMA), Procedure under Article 5(3) of Regulation EC (No) 726/2004: Nitrosamine impurities in human medicinal products. Procedure number: EMEA/H/A-5(3)/1490. EMA/369136/2020, 2020.
5. European Medicines Agency (EMA), Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. EMA/409815/2020, 2020.